Ziccum reports successful mRNA/LNP Feasibility Study with major Biotech Corporation
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Ziccum and its Biotech Corporation collaboration partner have now reviewed the outcomes of the LaminarPace Feasibility study of mRNA/LNP materials, under the agreement signed on May 9th 2023. The study was very successful, and both parties confirm consistent, positive readouts in the Study’s major parameters.
The joint assessment meeting reviewing the readouts took place on January 9, 2024. It concluded that the LaminarPace treatment performed very successfully in the Study’s agreed-upon metrics:
mRNA activity: the assessment concluded that the resulting dry powder material demonstrated excellent mRNA activity, when reconstituted and tested in in-vitro cell studies. This is a must for the resulting mRNA treatment to have its effect, for vaccine immunisation or therapeutic effect.
Encapsulation efficiency: the assessment concluded that the LaminarPace treatment resulted in well-preserved mRNA content in LNP particles with adequate encapsulation efficiency. This is an important metric in the production economics of mRNA/LNP, preserving the very expensive mRNA materials.
Particle preservation and distribution: the assessment concluded that the treatment resulted in well preserved lipid nanoparticles with good particle size and preserved size distribution. This is important for having a final drug composition which can be administered to patients.
Product reconstitution: the partner assessment confirmed the consistent Ziccum findings that LaminarPace-treated material can be reconstituted (dissolved back into liquid) very quickly and smoothly, with no foaming, precipitation, or other practical issues.
The Ziccum evaluation and the Biotech Corporation partner’s evaluation both delivered consistent results that matched very closely.
Based on these clear, satisfactory results, a continued dialogue on the potential next phase of collaboration in potential applications may be initiated.
Ziccum CEO Ann Gidner: “These results, from a world-leading player in the field, confirm LaminarPace’s ability to turn mRNA/LNP liquid biological material into a thermostable dry powder, with all its advantages, retaining excellent mRNA activity in cells. This is exciting and rewarding news. We are grateful for excellent partner interaction, and our partner concluding that the collaboration was a success. Let me express my appreciation to the Ziccum team for their great efforts delivering these results”.
Ziccum Chairman Fredrik Sjövall: “It is of utmost importance to Ziccum to have this validation of the applicability of LaminarPace technology also for mRNA/LNP treatments. We are keenly looking forward to the potential of applying LaminarPace in this field, with many potential applications and partners.”